Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Low-Dose Brachytherapy for Choroidal Melanoma: A Preliminary Report.

Ophthalmology. Retina·2026

Same author

Metastatic Uveal Melanoma Surveillance: A Delphi Panel Consensus.

Cancers·2026

Same author

Ultrasound Biomicroscopy in the Diagnosis and Management of Iris and Ciliary Body Tumors: A Comprehensive Review.

Ocular oncology and pathology·2025

Same author

Early-stage ocular toxocariasis: Progression and histopathologic analysis.

American journal of ophthalmology case reports·2025

Same author

Unifying Diagnosis of Choroidal Indeterminate Melanocytic Tumors-Reply.

JAMA ophthalmology·2025

Same author

Suprachoroidal Injection of Topotecan for Retinoblastoma: A Preclinical Study.

Ophthalmology science·2025

Search research articles

Related Experiment Video

Updated: Jul 7, 2026

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

Targeted therapy for uveal melanoma.

Pierre L Triozzi¹, Charis Eng, Arun D Singh

¹Taussig Cancer Center, The Cleveland Clinic Foundation, Cleveland, OH 44195, United States. triozzp@ccf.org

Cancer Treatment Reviews

|January 30, 2008

Summary

Uveal melanoma, a common eye cancer, has high mortality due to resistant metastasis. Molecularly targeted agents show promise for improving systemic therapy by inhibiting key tumor pathways, with clinical trials underway.

More Related Videos

Implantation and Evaluation of Melanoma in the Murine Choroid via Optical Coherence Tomography

Implantation and Evaluation of Melanoma in the Murine Choroid via Optical Coherence Tomography

Published on: December 2, 2022

Related Experiment Videos

Last Updated: Jul 7, 2026

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

Implantation and Evaluation of Melanoma in the Murine Choroid via Optical Coherence Tomography

Implantation and Evaluation of Melanoma in the Murine Choroid via Optical Coherence Tomography

Published on: December 2, 2022

Area of Science:

Ophthalmology
Oncology
Molecular Biology

Background:

Uveal melanoma is the most common primary intra-ocular malignancy in adults.
High mortality rates are linked to metastatic disease, which is resistant to systemic therapies.
Understanding cancer molecular pathogenesis drives development of targeted therapies.

Purpose of the Study:

To review prospects for improving uveal melanoma systemic therapy.
Focus on molecularly targeted agents in clinical use and trials.
Identify potential therapeutic targets in uveal melanoma.

Main Methods:

Review of preclinical studies on targeted agents.
Analysis of agents targeting apoptosis, proliferation, invasion, metastasis, and angiogenesis.
Examination of clinical trial data for metastatic and adjuvant settings.

Main Results:

Preclinical studies suggest benefits from inhibitors of Bcl-2, ubiquitin-proteasome, histone deacetylase, MAPK, PI3K-AKT pathways, and receptor tyrosine kinases.
Modifiers of adhesion molecules, matrix metalloproteinases, and angiogenic factors show potential.
Clinical trials have commenced for several targeted approaches.

Conclusions:

Molecularly targeted agents offer promising avenues for improving uveal melanoma systemic therapy.
Targeting specific molecular pathways is crucial for overcoming treatment resistance.
Ongoing clinical trials will determine the efficacy of these novel agents in patients.